Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect"

Cancer Gene Ther. 1996 Mar-Apr;3(2):83-8.

Abstract

The integration and expression of the herpes simplex virus type 1 thymidine kinase (HSV1-TK) gene in localized tumors results in tumor regression after the administration of the specific nucleoside analogue ganciclovir (GCV). Although only 10% to 20% of the tumor cells take up the HSV1-TK gene, the neighboring cells also die, a phenomenon termed "bystander effect.". In the present study, coinjection of the MC26 mouse colon carcinoma cell line and the HSV1-TK expressing retroviral packaging cell line followed after 7 days by the intraperitoneal administration of GCV resulted in almost total tumor regression in the immunocompetent BALB/c mice but not in immunocompromised athymic BALB/c mice. This suggested a strong cell-mediated immune component to the bystander effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / immunology*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Animals
  • CD4-CD8 Ratio
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / therapy*
  • Down-Regulation
  • Female
  • Ganciclovir / therapeutic use
  • Genetic Therapy / methods*
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • Immune Tolerance / immunology*
  • Immunohistochemistry
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Phenotype
  • Prodrugs / therapeutic use
  • Simplexvirus / drug effects
  • Simplexvirus / genetics
  • Statistics, Nonparametric
  • Thymidine Kinase / genetics
  • Tumor Cells, Cultured

Substances

  • Prodrugs
  • Thymidine Kinase
  • Ganciclovir